Free Trial
NASDAQ:SBFM

Sunshine Biopharma (SBFM) Stock Price, News & Analysis

$0.70
-0.06 (-7.93%)
(As of 04:00 PM ET)
Today's Range
$0.69
$0.76
50-Day Range
$0.74
$10.85
52-Week Range
$0.69
$67.01
Volume
1.86 million shs
Average Volume
1.92 million shs
Market Capitalization
$688,149.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$260.00

Sunshine Biopharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
36,753.3% Upside
$260.00 Price Target
Short Interest
Healthy
0.97% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.31mentions of Sunshine Biopharma in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$10,000 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.45 out of 5 stars

SBFM stock logo

About Sunshine Biopharma Stock (NASDAQ:SBFM)

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.

SBFM Stock Price History

SBFM Stock News Headlines

Sunshine Biopharma (NASDAQ:SBFM) Trading 4.5% Higher
SBFM Sunshine Biopharma, Inc.
Sunshine Biopharma Incorporated
What Are Sunshine Laws? Definition, Purpose, Examples
See More Headlines
Receive SBFM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sunshine Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/28/2024
Today
5/28/2024
Next Earnings (Estimated)
8/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SBFM
Fax
N/A
Employees
44
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$260.00
High Stock Price Target
$260.00
Low Stock Price Target
$260.00
Potential Upside/Downside
+35,035.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-4,510,000.00
Pretax Margin
-13.90%

Debt

Sales & Book Value

Annual Sales
$24.09 million
Book Value
$82.58 per share

Miscellaneous

Free Float
954,000
Market Cap
$732,600.00
Optionable
Not Optionable
Beta
1.64
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Steve N. Slilaty Ph.D. (Age 72)
    CEO, President & Chairman
    Comp: $640k
  • Mr. Camille Sebaaly (Age 65)
    CFO & Secretary
    Comp: $695k
  • Dr. Abderrazzak Merzouki (Age 60)
    Chief Science Officer & Director
    Comp: $340k
  • Mr. Marc Beaudoin (Age 57)
    Chief Operating Officer
  • Mr. Malek Chamoun (Age 39)
    Chief Development Officer
  • Mr. Robert G. Ferreira (Age 62)
    President of Sunshine Bio Investments Inc

SBFM Stock Analysis - Frequently Asked Questions

Should I buy or sell Sunshine Biopharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sunshine Biopharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SBFM shares.
View SBFM analyst ratings
or view top-rated stocks.

What is Sunshine Biopharma's stock price target for 2024?

1 analysts have issued 1-year target prices for Sunshine Biopharma's stock. Their SBFM share price targets range from $260.00 to $260.00. On average, they anticipate the company's share price to reach $260.00 in the next twelve months. This suggests a possible upside of 36,753.3% from the stock's current price.
View analysts price targets for SBFM
or view top-rated stocks among Wall Street analysts.

How have SBFM shares performed in 2024?

Sunshine Biopharma's stock was trading at $27.15 on January 1st, 2024. Since then, SBFM shares have decreased by 97.4% and is now trading at $0.7055.
View the best growth stocks for 2024 here
.

Are investors shorting Sunshine Biopharma?

Sunshine Biopharma saw a drop in short interest in May. As of May 15th, there was short interest totaling 176,300 shares, a drop of 38.0% from the April 30th total of 284,500 shares. Based on an average trading volume of 2,970,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 1.0% of the shares of the stock are short sold.
View Sunshine Biopharma's Short Interest
.

When is Sunshine Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024.
View our SBFM earnings forecast
.

How were Sunshine Biopharma's earnings last quarter?

Sunshine Biopharma, Inc. (NASDAQ:SBFM) posted its earnings results on Thursday, March, 28th. The company reported ($5.00) earnings per share (EPS) for the quarter. The firm earned $7.68 million during the quarter. Sunshine Biopharma had a negative trailing twelve-month return on equity of 17.95% and a negative net margin of 15.29%.

When did Sunshine Biopharma's stock split?

Sunshine Biopharma's stock reverse split on the morning of Wednesday, April 17th 2024. The 1-100 reverse split was announced on Wednesday, April 17th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of Sunshine Biopharma?

Shares of SBFM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SBFM) was last updated on 5/28/2024 by MarketBeat.com Staff

From Our Partners